Literature DB >> 20213306

Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.

Michael Groessl1, Yury O Tsybin, Christian G Hartinger, Bernhard K Keppler, Paul J Dyson.   

Abstract

The binding of the an class="Chemical">ruthenium-based antian class="Disease">cancer drug candidates KP1019, NAMI-A and RAPTA-T towards different double-stranded oligonucleotides was probed by electrospray ionisation mass spectrometry and compared with that of the widely used platinum-based chemotherapeutics cisplatin, carboplatin and oxaliplatin. It was found that the extent of adduct formation decreased in the following order: cisplatin > oxaliplatin > NAMI-A > RAPTA-T > carboplatin > KP1019. In addition to the characterisation of the adducts formed with the DNA models, the binding sites of the metallodrugs on the oligonucleotides were elucidated employing top-down tandem mass spectrometry and were found to be similar for all the metallodrugs studied, irrespective of the sequence of the oligonucleotide. A strong preference for guanine residues was established.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213306      PMCID: PMC6485486          DOI: 10.1007/s00775-010-0635-0

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  38 in total

1.  Mass spectrometry of nucleic acids.

Authors:  E Nordhoff; F Kirpekar; P Roepstorff
Journal:  Mass Spectrom Rev       Date:  1996       Impact factor: 10.946

2.  Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.

Authors:  Wee Han Ang; Elisa Daldini; Claudine Scolaro; Rosario Scopelliti; Lucienne Juillerat-Jeannerat; Paul J Dyson
Journal:  Inorg Chem       Date:  2006-10-30       Impact factor: 5.165

3.  Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media.

Authors:  J Malina; O Novakova; B K Keppler; E Alessio; V Brabec
Journal:  J Biol Inorg Chem       Date:  2001-04       Impact factor: 3.358

4.  Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.

Authors:  Michael Groessl; Erwin Reisner; Christian G Hartinger; Rene Eichinger; Olga Semenova; Andrei R Timerbaev; Michael A Jakupec; Vladimir B Arion; Bernhard K Keppler
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

Review 5.  Metal-based antitumour drugs in the post genomic era.

Authors:  Paul J Dyson; Gianni Sava
Journal:  Dalton Trans       Date:  2006-03-28       Impact factor: 4.390

6.  Interpretation of oligonucleotide mass spectra for determination of sequence using electrospray ionization and tandem mass spectrometry.

Authors:  J Ni; C Pomerantz; J Rozenski; Y Zhang; J A McCloskey
Journal:  Anal Chem       Date:  1996-07-01       Impact factor: 6.986

7.  Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.

Authors:  Jana Kasparkova; Marie Vojtiskova; Giovanni Natile; Viktor Brabec
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

8.  High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides.

Authors:  Alexander E Egger; Christian G Hartinger; Hisham Ben Hamidane; Yury O Tsybin; Bernhard K Keppler; Paul J Dyson
Journal:  Inorg Chem       Date:  2008-10-24       Impact factor: 5.165

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  The influence of Cisplatin on the gas-phase dissociation of oligonucleotides studied by electrospray ionization tandem mass spectrometry.

Authors:  Adrien Nyakas; Michael Eymann; Stefan Schürch
Journal:  J Am Soc Mass Spectrom       Date:  2008-12-31       Impact factor: 3.262

View more
  14 in total

1.  Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.

Authors:  Alethia A Hostetter; Michelle L Miranda; Victoria J DeRose; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2011-07-08       Impact factor: 3.358

2.  Insights into the binding sites of organometallic ruthenium anticancer compounds on peptides using ultra-high resolution mass spectrometry.

Authors:  Rebecca H Wills; Abraha Habtemariam; Andrea F Lopez-Clavijo; Mark P Barrow; Peter J Sadler; Peter B O'Connor
Journal:  J Am Soc Mass Spectrom       Date:  2014-02-01       Impact factor: 3.109

3.  Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.

Authors:  Leticia Cubo; Michael Groessl; Paul J Dyson; Adoración G Quiroga; Carmen Navarro-Ranninger; Angela Casini
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

4.  Reactions of Ru(III)-drugs KP1019 and KP418 with guanine, 2'-deoxyguanosine and guanosine: a DFT study.

Authors:  Pramod Kumar Shah; Nihar R Jena; Pradeep Kumar Shukla
Journal:  J Mol Model       Date:  2022-09-05       Impact factor: 2.172

5.  Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Authors:  L Brescacin; A Masi; G Sava; A Bergamo
Journal:  J Biol Inorg Chem       Date:  2015-09-14       Impact factor: 3.358

6.  Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.

Authors:  Kui Wu; Wenbing Hu; Qun Luo; Xianchan Li; Shaoxiang Xiong; Peter J Sadler; Fuyi Wang
Journal:  J Am Soc Mass Spectrom       Date:  2013-02-13       Impact factor: 3.109

7.  Comparison of MS/MS methods for characterization of DNA/cisplatin adducts.

Authors:  Zhe Xu; Jared B Shaw; Jennifer S Brodbelt
Journal:  J Am Soc Mass Spectrom       Date:  2012-12-20       Impact factor: 3.109

8.  OMA and OPA--software-supported mass spectra analysis of native and modified nucleic acids.

Authors:  Adrien Nyakas; Lorenz C Blum; Silvan R Stucki; Jean-Louis Reymond; Stefan Schürch
Journal:  J Am Soc Mass Spectrom       Date:  2012-12-21       Impact factor: 3.109

9.  Preliminary anti-cancer photodynamic therapeutic in vitro studies with mixed-metal binuclear ruthenium(II)-vanadium(IV) complexes.

Authors:  Alvin A Holder; Patrick Taylor; Anthony R Magnusen; Erick T Moffett; Kyle Meyer; Yiling Hong; Stuart E Ramsdale; Michelle Gordon; Javelyn Stubbs; Luke A Seymour; Dhiraj Acharya; Ralph T Weber; Paul F Smith; G Charles Dismukes; Ping Ji; Laura Menocal; Fengwei Bai; Jennie L Williams; Donald M Cropek; William L Jarrett
Journal:  Dalton Trans       Date:  2013-09-07       Impact factor: 4.390

10.  Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)].

Authors:  Korawan Chakree; Chitchamai Ovatlarnporn; Paul J Dyson; Adisorn Ratanaphan
Journal:  Int J Mol Sci       Date:  2012-10-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.